The Motley Fool•10 Kasım 2026Gilead Sciences stock surges 38% year-to-date, outperforming the S&P 500
The Motley Fool•1 Kasım 2026Gilead Sciences recommended as November dividend stock after strong Q3 earnings
The Motley Fool•18 Ekim 2026Gilead Sciences stock climbs nearly 30% on strong earnings and FDA approvals
Yahoo Finance•20 Eylül 2026Morgan Stanley reiterates positive view on Gilead, citing HIV prevention drug Yeztugo